Modulation of T-cell activation by malignant melanoma initiating cells

Cancer Research

Volumn 70, Issue 2, 2010, Pages 697-708

  Schatton, Tobias ^a   Schütte, Ute ^a   Frank, Natasha Y ^a,c   Zhan, Qian ^a   Hoerning, André ^a   Robles, Susanne C ^a   Zhou, Jun ^b   Hodi, F Stephen ^b   Spagnoli, Giulio C ^d   Murphy, George F ^a   Frank, Markus H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; LIVIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENIC ACTIVITY; CD4+ CD25+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CELL SUBPOPULATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNOASSAY; IMMUNOMODULATION; MELANOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THERAPY RESISTANCE; TUMOR IMMUNITY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; P-GLYCOPROTEIN; T-LYMPHOCYTES, REGULATORY;

EID: 76549126237     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1592     Document Type: Article

References (50)

1. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009;15:1010-2.
2. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays 2009;31:1038-49.
3. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68:6043-8.
4. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 2009;106: 14016-21.
5. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-59.
6. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9.
7. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23.
8. Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 2008;21:39-55.
9. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65:4320-33.
10. Huang Y, Anderle P, Bussey KJ, et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301.
11. Elliott AM, Al-Hajj MA. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res 2009;7:79-87.
12. Botelho MG, Wang X, Arndt-Jovin DJ, Becker D, Jovin TM. Induction of terminal differentiation in melanoma cells on down-regulation of β-amyloid precursor protein. J Invest Dermatol. Epub 2009 Sept 17.
13. Keshet GI, Goldstein I, Itzhaki O, et al. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 2008;368:930-6.
14. Hoek KS, Eichhoff OM, Widmer D, Dummer R. Stemming the flood. Pigment Cell Melanoma Res 2009;22:6-7.
15. Sousa JF, Espreafico EM. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer 2008;8:19.
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
17. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
18. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008;456:593-8.
19. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008;112:568-75.
20. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22: 1136-51.
21. Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 2009;1176:154-69.
22. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-3.
23. Frank MH, Sayegh MH. Immunomodulatory functions of mesenchymal stem cells. Lancet 2004;363:1411-2.
24. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41.
25. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev 2003;196:85-108.
26. Frank NY, Kho AT, Schatton T, et al. Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. J Cell Biol 2006;175:99-110.
27. Kocher T, Schultz-Thater E, Gudat F, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-9.
28. Schultz-Thater E, Noppen C, Gudat F, et al. NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 2000;83:204-8.
29. Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am J Transplant 2006;6:2884-93.
30. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84:1415-20.
31. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 2007;601:123-31.
32. Cabrera T, Lara E, Romero JM, et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007;56:709-17.
33. Carretero R, Romero JM, Ruiz-Cabello F, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008;60:439-47.
34. van Houdt IS, Sluijter BJ, Moesbergen LM, et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 2008;123:609-15.
35. Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003;100:3398-403.
36. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
37. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-83.
38. + T cells. Immunol Rev 2006;211:81-92.
39. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
40. Abdel-Wahab Z, Li WP, Osanto S, et al. Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol 1994;159:26-39.
41. Zatloukal K, Schneeberger A, Berger M, et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 1995;154:3406-19.
42. + melanoma cells. Cancer Immunol Immunother 2009;58:1635-46.
43. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-73.
44. Hombach AA, Kofler D, Hombach A, Rappl G, Abken H. Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol 2007;179:7924-31.
45. Tsukahara R, Takeuchi M, Akiba H, et al. Critical contribution of CD80 and CD86 to induction of anterior chamber-associated immune deviation. Int Immunol 2005;17:523-30.
46. + Treg population via TGF-β3. Eur J Immunol 2008;38:2488-98.
47. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines α-melanocyte-stimulating hormone and transforming growth factor-β2. J Leukoc Biol 2002;72: 946-52.
48. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007;25:3802-7.
49. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008;26:3445-55.
50. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.